Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This designation underscores the urgency of bringing differentiated treatment options to patients and will help accelerate the development of PYX-201 as we actively recruit patients for our trial,
(RTTNews) - Pyxis Oncology, Inc. (PYXS) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201, the company's drug candidate for the ...
Two PYX-201 trials are now actively recruiting and are designed to evaluate PYX-201 as monotherapy in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC ...
Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have received an average recommendation of “Moderate Buy” from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback